Source: Dechra
Dechra announced on November 9, 2026, that it has signed an agreement to acquire Gallant Pet, Inc., a U.S.-based Animal Health biotechnology company specializing in regenerative medicine for companion animals. The acquisition supports Dechra’s long-term strategy to address unmet medical needs in specialty Veterinary care and expand its capabilities in innovative treatment technologies.
Gallant Pet has established itself as a leader in developing off-the-shelf mesenchymal stromal cell therapies for pets. These regenerative therapies represent an emerging area of Veterinary medicine with the potential to provide additional treatment options for animals.
By integrating Gallant Pet’s expertise and technology, Dechra aims to strengthen its position in specialty Animal Health care while advancing animal health and welfare. The company also expects the acquisition to support sustainable business growth. The transaction remains subject to customary closing conditions, and both companies have agreed to keep the financial and other terms of the acquisition confidential.
Read the full story HERE: https://www.dechra.com/news/2026/november/dechra-announces-agreement-to-acquire-gallant-pet-inc